BioCentury
ARTICLE | Top Story

CoLucid soars on Phase III migraine readout

September 6, 2016 7:00 AM UTC

CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) rocketed $13.17 (124%) to $23.83 on Tuesday after reporting that both doses of lasmiditan (oral COL-144) met the primary endpoint in the Phase III SAMURAI trial to treat acute migraine.

In the study, 28.2% of patients receiving 100 mg of lasmiditan and 32.2% of those receiving 200 mg were free of headache pain two hours after dosing, the primary endpoint, compared to 15.3% of patients who received placebo (p<0.001 for both doses). ...